Small Molecule Inhibitors of the Poxvirus Type I Interferon Binding Protein
I 型痘病毒干扰素结合蛋白的小分子抑制剂
基本信息
- 批准号:8539743
- 负责人:
- 金额:$ 20.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-04 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:AfricaAnimal ModelAntiviral AgentsAreaBindingBinding ProteinsBinding SitesBiologicalBioterrorismBrazilCell surfaceCellsCharacteristicsChemicalsCowpoxCowpox virusDevelopmentDiseaseDrug KineticsEmergency SituationEndemic DiseasesGoalsHealthHumanImmune responseIn VitroIndiaInfectionInfectious EctromeliaInterferon Type IInterferonsLeadLeftModelingMonkeypoxMonkeypox virusMonoclonal AntibodiesMouse Pox VirusMusOral AdministrationOrthopoxvirusOryctolagus cuniculusPathogenesisPharmaceutical PreparationsPositioning AttributePoxviridaeProductionResearchRiskSmallpoxSmallpox VirusesSolubilityStagingTestingToxic effectVaccinationVaccinesVaccinia virusViralViral PhysiologyVirulenceVirusWorkZoonosesbasedrug candidateeffective therapyextracellularhigh throughput screeningimprovedin vivoinhibitor/antagonistnonhuman primatenovelpathogenpreventprotein protein interactionreceptorsmall moleculetissue culture
项目摘要
DESCRIPTION (provided by applicant): The genus Orthopoxvirus (OPV) includes, among others, the human pathogen variola virus (VARV), the zoonotic viruses monkeypox (MPXV) and cowpox virus (CPXV)~ the vaccine species vaccinia virus (VAC) which is also responsible for zoonoses in Brazil and India, and the mouse pathogen Ectromelia virus (ECTV) that causes mousepox in mice and is an outstanding model for human smallpox. All OPVs encode a highly conserved (~87% identical residues) Type 1 interferon (T1-IFN) binding protein (herein T1-IFN bp) that is secreted from infected cells to act as a decoy receptor for T1-IFN in the extracellular milieu and at the cell surface. In this way, the T1-IFNbp suppresses the anti-viral activity of T1-IFN. Using ECTV as a model, we previously showed that T1-IFN bp is essential for OPV virulence and an effective target for vaccination. New preliminary results show that an anti-T1-IFNbp monoclonal antibody (mAb) that inhibits the binding of T1-IFN bp to T1-IFN (but not a non-inhibitory mAb) can cure lethal mousepox when given as late as 5 days post infection (dpi). This suggests the new and exciting possibility that disruption of 1-IFNbp-T1-IFN binding could be an effective treatment for human OPV infections. However, treatment with mouse mAbs is not ideal because they are expensive and can cause an undesirable immune response in humans. Small molecule pharmacological inhibitors of T1-IFN bp would be a much better approach. Hence, we will screen for small molecules that inhibit T1-IFN bp-T1-IFN (Aim 1) and test them for their ability to cure mousepox, an outstanding small animal model for OPV disease (Aim 2). If successful, these drug candidates could be tested in additional OPV animal models as surrogates of human OPV disease. Developing a new simple pharmacological agent against OPVs should have an impact for human health in areas of endemic and zoonotic MPXV, CPXV, VACV and buffalopox virus and may be of extreme importance in case of emerging OPVs or bioterrorist attacks.
描述(申请人提供):正痘病毒属(OPV)包括人类病原体天花病毒(VARV)、人畜共患病毒猴痘(MPXV)和牛痘病毒(CPXV)-疫苗种牛痘病毒(VAC),其也是巴西和印度人畜共患疾病的原因,以及小鼠病原体鼠痘病毒(ECTV),其在小鼠中引起小鼠痘,并且是人类天花的杰出模型。所有OPV编码高度保守(~87%相同残基)的1型干扰素(T1-IFN)结合蛋白(本文中T1-IFN bp),其从感染的细胞分泌以在细胞外环境中和在细胞表面充当T1-IFN的诱饵受体。以这种方式,T1-IFNbp抑制T1-IFN的抗病毒活性。使用ECTV作为模型,我们先前表明T1-IFN bp对于OPV毒力是必不可少的,并且是疫苗接种的有效靶标。 新的初步结果表明,抑制T1-IFNbp与T1-IFNbp结合的抗T1-IFNbp单克隆抗体(mAb)(但非抑制性mAb)最迟在感染后5天给予时可以治愈致命的小鼠痘(dpi)。 这表明了新的和令人兴奋的可能性,即1-IFNbp-T1-IFN结合的破坏可能是人类OPV感染的有效治疗。然而,用小鼠单克隆抗体治疗并不理想,因为它们昂贵并且可能在人体中引起不期望的免疫应答。T1-IFN bp的小分子药理学抑制剂将是更好的方法。因此,我们将筛选抑制T1-IFN bp-T1-IFN的小分子(目标1),并测试它们治愈小鼠痘的能力,小鼠痘是OPV疾病的杰出小动物模型(目标2)。如果成功,这些候选药物可以在其他OPV动物模型中作为人类OPV疾病的替代物进行测试。开发一种新的抗口服脊髓灰质炎病毒的简单药物制剂,应能对地方性和人畜共患MPXV、CPXV、VACV和水牛痘病毒地区的人类健康产生影响,在出现口服脊髓灰质炎病毒或生物恐怖袭击的情况下可能极为重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY R PETERSON其他文献
JEFFREY R PETERSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY R PETERSON', 18)}}的其他基金
Small Molecule Inhibitors of the Poxvirus Type I Interferon Binding Protein
I 型痘病毒干扰素结合蛋白的小分子抑制剂
- 批准号:
8401099 - 财政年份:2012
- 资助金额:
$ 20.97万 - 项目类别:
Specificity of Effector Activation by Rho Family GTPases
Rho 家族 GTP 酶激活效应器的特异性
- 批准号:
7935555 - 财政年份:2009
- 资助金额:
$ 20.97万 - 项目类别:
Specificity of Effector Activation by Rho Family GTPases
Rho 家族 GTP 酶激活效应器的特异性
- 批准号:
8144248 - 财政年份:2008
- 资助金额:
$ 20.97万 - 项目类别:
Specificity of Effector Activation by Rho Family GTPases
Rho 家族 GTP 酶激活效应器的特异性
- 批准号:
7685476 - 财政年份:2008
- 资助金额:
$ 20.97万 - 项目类别:
Specificity of Effector Activation by Rho Family GTPases
Rho 家族 GTP 酶激活效应器的特异性
- 批准号:
7924893 - 财政年份:2008
- 资助金额:
$ 20.97万 - 项目类别:
Specificity of Effector Activation by Rho Family GTPases
Rho 家族 GTP 酶激活效应器的特异性
- 批准号:
7524479 - 财政年份:2008
- 资助金额:
$ 20.97万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 20.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




